We also found that all patients presented systemic CD4 T cells with mainly Th17 phenotypes, without differences between responders and progressors, and without significant differences in the percentage of lung-cancer-specific CD4 or CD8 T cells [8]. This evidence concerns the gene CD4 and lung cancer.